Estudio de fase III, abierto, de Dato-DXd de primera línea en combinación con rilvegostomig para el NSCLC no escamoso avanzado con alta expresión de PD-L1 (TC ≥ 50%) y sin alteraciones genómicas procesables (TROPION-Lung10)
Un estudio global de fase III, aleatorizado, abierto, de datopotamab deruxtecan (Dato-DXd) en combinación con rilvegostomig o monoterapia con rilvegostomig versus monoterapia con pembrolizumab para el tratamiento de primera línea de participantes con NSCLC no escamoso localmente avanzado o metastásico con alta Expresión de PD-L1 (TC ≥ 50%) y sin alteraciones genómicas procesables (TROPION-Lung10)
The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced or metastatic non-squamous NSCLC with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
This is a Phase III, randomized, open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig monotherapy compared with Pembrolizumab monotherapy for the first-line treatment of participants with locally-advanced or metastatic non-squamous NSCLC with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- Fase 3
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: AstraZeneca Clinical Study Information Center
- Número de teléfono: 1-877-240-9479
- Correo electrónico: information.center@astrazeneca.com
Ubicaciones de estudio
-
-
-
Berlin, Alemania, 10249
- Aún no reclutando
- Research Site
-
Bonn, Alemania, 53113
- Reclutamiento
- Research Site
-
Cologne, Alemania, 50677
- Reclutamiento
- Research Site
-
Düsseldorf, Alemania, 40489
- Retirado
- Research Site
-
Essen, Alemania, 45136
- Reclutamiento
- Research Site
-
Freiburg im Breisgau, Alemania, 79106
- Reclutamiento
- Research Site
-
Gauting, Alemania, 82131
- Reclutamiento
- Research Site
-
Georgsmarienhütte, Alemania, 49124
- Retirado
- Research Site
-
Gera, Alemania, 07548
- Retirado
- Research Site
-
Gütersloh, Alemania, 33332
- Retirado
- Research Site
-
Hamburg, Alemania, 20251
- Reclutamiento
- Research Site
-
Hamburg, Alemania, 22087
- Reclutamiento
- Research Site
-
Heidelberg, Alemania, 69126
- Reclutamiento
- Research Site
-
Kempten, Alemania, 87439
- Suspendido
- Research Site
-
Kiel, Alemania, 24116
- Aún no reclutando
- Research Site
-
Koblenz, Alemania, 56068
- Suspendido
- Research Site
-
Ludwigsburg, Alemania, 71640
- Retirado
- Research Site
-
München, Alemania, 81925
- Reclutamiento
- Research Site
-
Nuremberg, Alemania, 90419
- Retirado
- Research Site
-
Potsdam, Alemania, 14467
- Reclutamiento
- Research Site
-
Ravensburg, Alemania, 88212
- Reclutamiento
- Research Site
-
-
-
-
-
Birtinya, Australia, 4575
- Retirado
- Research Site
-
Blacktown, Australia, 2148
- Retirado
- Research Site
-
Clayton, Australia, 3168
- Reclutamiento
- Research Site
-
Gosford, Australia, 2250
- Reclutamiento
- Research Site
-
Melbourne, Australia, 3000
- Retirado
- Research Site
-
South Brisbane, Australia, QL 4101
- Reclutamiento
- Research Site
-
Wodonga, Australia, 3690
- Reclutamiento
- Research Site
-
-
-
-
-
Innsbruck, Austria, 6020
- Reclutamiento
- Research Site
-
Krems, Austria, 3500
- Reclutamiento
- Research Site
-
Linz, Austria, 4020
- Reclutamiento
- Research Site
-
Rankweil, Austria, 6830
- Reclutamiento
- Research Site
-
Vienna, Austria, 1210
- Reclutamiento
- Research Site
-
Vienna, Austria, 1140
- Reclutamiento
- Research Site
-
Wels, Austria, 4600
- Retirado
- Research Site
-
-
-
-
-
Barretos, Brasil, 14784-400
- Reclutamiento
- Research Site
-
Curitiba, Brasil, 80730-150
- Reclutamiento
- Research Site
-
Florianópolis, Brasil, 88034-000
- Reclutamiento
- Research Site
-
Ipatinga, Brasil, 35162-189
- Reclutamiento
- Research Site
-
Natal, Brasil, 59075-740
- Reclutamiento
- Research Site
-
Porto Alegre, Brasil, 91350-200
- Reclutamiento
- Research Site
-
Rio de Janeiro, Brasil, 22211-230
- Reclutamiento
- Research Site
-
Santa Maria, Brasil, 97015-450
- Reclutamiento
- Research Site
-
São Paulo, Brasil, 01221-020
- Reclutamiento
- Research Site
-
Taubaté, Brasil, 12030-200
- Reclutamiento
- Research Site
-
-
-
-
-
Anderlecht, Bélgica, 1070
- Retirado
- Research Site
-
Bruges, Bélgica, 8000
- Reclutamiento
- Research Site
-
Hasselt, Bélgica, 3500
- Reclutamiento
- Research Site
-
La Louvière, Bélgica, 7100
- Reclutamiento
- Research Site
-
Liège, Bélgica, 4000
- Reclutamiento
- Research Site
-
-
-
-
-
Chicoutimi, Canadá, G7H 5H6
- Reclutamiento
- Research Site
-
-
British Columbia
-
Vancouver, British Columbia, Canadá, VSZ 4E6
- Reclutamiento
- Research Site
-
-
Manitoba
-
Winnipeg, Manitoba, Canadá, R3E 0V9
- Retirado
- Research Site
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, Canadá, A1B 3V6
- Reclutamiento
- Research Site
-
-
Ontario
-
London, Ontario, Canadá, N6A 4L6
- Reclutamiento
- Research Site
-
Newmarket, Ontario, Canadá, L3Y 2P9
- Retirado
- Research Site
-
Oshawa, Ontario, Canadá, L1G 2B9
- Reclutamiento
- Research Site
-
Toronto, Ontario, Canadá, M4N 3M5
- Retirado
- Research Site
-
-
Quebec
-
Lévis, Quebec, Canadá, G6V 0B8
- Reclutamiento
- Research Site
-
Montreal, Quebec, Canadá, H4J 1C5
- Reclutamiento
- Research Site
-
Montreal, Quebec, Canadá, H3T 1E2
- Reclutamiento
- Research Site
-
Montreal, Quebec, Canadá, H3T 1M5
- Retirado
- Research Site
-
Rimouski, Quebec, Canadá, G5L 5T1
- Reclutamiento
- Research Site
-
Trois-Rivières, Quebec, Canadá, G8Z 3R9
- Reclutamiento
- Research Site
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Canadá, S7N 4H4
- Reclutamiento
- Research Site
-
-
-
-
-
Changwon, Corea del Sur, 51353
- Reclutamiento
- Research Site
-
Incheon, Corea del Sur, 21565
- Reclutamiento
- Research Site
-
Seongnam-si, Corea del Sur, 13496
- Reclutamiento
- Research Site
-
Seoul, Corea del Sur, 03080
- Reclutamiento
- Research Site
-
Seoul, Corea del Sur, 03722
- Reclutamiento
- Research Site
-
Seoul, Corea del Sur, 08308
- Aún no reclutando
- Research Site
-
Seoul, Corea del Sur, 06973
- Reclutamiento
- Research Site
-
Suwon, Corea del Sur, 16247
- Reclutamiento
- Research Site
-
Suwon, Corea del Sur, 16499
- Reclutamiento
- Research Site
-
-
-
-
-
Alicante, España, 03010
- Reclutamiento
- Research Site
-
Barcelona, España, 08036
- Reclutamiento
- Research Site
-
Barcelona, España, 08003
- Reclutamiento
- Research Site
-
Barcelona, España, 08041
- Aún no reclutando
- Research Site
-
Jerez de la Frontera, España, 11407
- Reclutamiento
- Research Site
-
Reus, España, 43204
- Reclutamiento
- Research Site
-
Salamanca, España, 37007
- Retirado
- Research Site
-
-
-
-
Alaska
-
Anchorage, Alaska, Estados Unidos, 99508
- Reclutamiento
- Research Site
-
-
Arizona
-
Tucson, Arizona, Estados Unidos, 85719
- Reclutamiento
- Research Site
-
-
Arkansas
-
Little Rock, Arkansas, Estados Unidos, 72205
- Reclutamiento
- Research Site
-
Springdale, Arkansas, Estados Unidos, 72762
- Reclutamiento
- Research Site
-
-
California
-
Anaheim, California, Estados Unidos, 92801
- Reclutamiento
- Research Site
-
Beverly Hills, California, Estados Unidos, 90211
- Reclutamiento
- Research Site
-
Fountain Valley, California, Estados Unidos, 92708
- Reclutamiento
- Research Site
-
Newport Beach, California, Estados Unidos, 92663
- Suspendido
- Research Site
-
-
Florida
-
Clermont, Florida, Estados Unidos, 34711
- Reclutamiento
- Research Site
-
Gainesville, Florida, Estados Unidos, 32608
- Reclutamiento
- Research Site
-
Miami Beach, Florida, Estados Unidos, 33140
- Reclutamiento
- Research Site
-
Orange City, Florida, Estados Unidos, 32763
- Reclutamiento
- Research Site
-
Orlando, Florida, Estados Unidos, 32806
- Reclutamiento
- Research Site
-
Orlando, Florida, Estados Unidos, 32827
- Retirado
- Research Site
-
West Palm Beach, Florida, Estados Unidos, 33401
- Reclutamiento
- Research Site
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30322
- Reclutamiento
- Research Site
-
Atlanta, Georgia, Estados Unidos, 30318
- Reclutamiento
- Research Site
-
Atlanta, Georgia, Estados Unidos, 30342
- Retirado
- Research Site
-
Atlanta, Georgia, Estados Unidos, 30303
- Suspendido
- Research Site
-
-
Illinois
-
Hinsdale, Illinois, Estados Unidos, 60521
- Reclutamiento
- Research Site
-
-
Indiana
-
Noblesville, Indiana, Estados Unidos, 46062
- Reclutamiento
- Research Site
-
-
Kentucky
-
Paducah, Kentucky, Estados Unidos, 42003
- Reclutamiento
- Research Site
-
-
Maryland
-
Annapolis, Maryland, Estados Unidos, 21401
- Reclutamiento
- Research Site
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02215
- Reclutamiento
- Research Site
-
Boston, Massachusetts, Estados Unidos, 02114
- Reclutamiento
- Research Site
-
-
Michigan
-
Dearborn, Michigan, Estados Unidos, 48126
- Reclutamiento
- Research Site
-
Farmington Hills, Michigan, Estados Unidos, 48334
- Reclutamiento
- Research Site
-
Grand Rapids, Michigan, Estados Unidos, 49503
- Reclutamiento
- Research Site
-
Traverse City, Michigan, Estados Unidos, 49684
- Retirado
- Research Site
-
-
Mississippi
-
Hattiesburg, Mississippi, Estados Unidos, 39401
- Reclutamiento
- Research Site
-
-
Missouri
-
Kansas City, Missouri, Estados Unidos, 64132
- Reclutamiento
- Research Site
-
-
Montana
-
Bozeman, Montana, Estados Unidos, 59715
- Retirado
- Research Site
-
-
Nebraska
-
Grand Island, Nebraska, Estados Unidos, 68803
- Reclutamiento
- Research Site
-
Omaha, Nebraska, Estados Unidos, 68130
- Reclutamiento
- Research Site
-
-
Nevada
-
Las Vegas, Nevada, Estados Unidos, 89102
- Reclutamiento
- Research Site
-
Reno, Nevada, Estados Unidos, 89502
- Retirado
- Research Site
-
-
New Jersey
-
Voorhees Township, New Jersey, Estados Unidos, 08043
- Suspendido
- Research Site
-
-
New York
-
Stony Brook, New York, Estados Unidos, 11794
- Reclutamiento
- Research Site
-
-
North Carolina
-
Greenville, North Carolina, Estados Unidos, 27834
- Reclutamiento
- Research Site
-
Salisbury, North Carolina, Estados Unidos, 28144
- Reclutamiento
- Research Site
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos, 45219
- Reclutamiento
- Research Site
-
Columbus, Ohio, Estados Unidos, 43210
- Retirado
- Research Site
-
Maumee, Ohio, Estados Unidos, 43537
- Reclutamiento
- Research Site
-
Toledo, Ohio, Estados Unidos, 43623
- Reclutamiento
- Research Site
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97213
- Retirado
- Research Site
-
-
South Carolina
-
Greenville, South Carolina, Estados Unidos, 29607
- Reclutamiento
- Research Site
-
-
South Dakota
-
Sioux Falls, South Dakota, Estados Unidos, 57105
- Reclutamiento
- Research Site
-
-
Tennessee
-
Chattanooga, Tennessee, Estados Unidos, 37404
- Retirado
- Research Site
-
Knoxville, Tennessee, Estados Unidos, 37920
- Retirado
- Research Site
-
-
Texas
-
Fort Worth, Texas, Estados Unidos, 76104
- Reclutamiento
- Research Site
-
Houston, Texas, Estados Unidos, 77030
- Reclutamiento
- Research Site
-
Houston, Texas, Estados Unidos, 77030
- Retirado
- Research Site
-
Houston, Texas, Estados Unidos, 77090
- Suspendido
- Research Site
-
Kingwood, Texas, Estados Unidos, 77339
- Reclutamiento
- Research Site
-
Odessa, Texas, Estados Unidos, 79761
- Reclutamiento
- Research Site
-
-
Virginia
-
Fort Belvoir, Virginia, Estados Unidos, 22060
- Reclutamiento
- Research Site
-
Leesburg, Virginia, Estados Unidos, 20176
- Reclutamiento
- Research Site
-
Midlothian, Virginia, Estados Unidos, 23114
- Reclutamiento
- Research Site
-
Richmond, Virginia, Estados Unidos, 23230
- Reclutamiento
- Research Site
-
-
Washington
-
Tacoma, Washington, Estados Unidos, 98405
- Reclutamiento
- Research Site
-
Vancouver, Washington, Estados Unidos, 98684
- Reclutamiento
- Research Site
-
Wenatchee, Washington, Estados Unidos, 98801
- Reclutamiento
- Research Site
-
-
Wisconsin
-
Appleton, Wisconsin, Estados Unidos, 54911
- Reclutamiento
- Research Site
-
-
-
-
-
Budapest, Hungría, 1121
- Reclutamiento
- Research Site
-
Edelény, Hungría, 3780
- Aún no reclutando
- Research Site
-
Gyula, Hungría, 5700
- Suspendido
- Research Site
-
Gyöngyös, Hungría, 3200
- Retirado
- Research Site
-
Gyöngyös - Mátraháza, Hungría, 3200
- Reclutamiento
- Research Site
-
Győr, Hungría, 9024
- Reclutamiento
- Research Site
-
Kecskemét, Hungría, 6000
- Reclutamiento
- Research Site
-
Salgótarján, Hungría, 3100
- Retirado
- Research Site
-
Szekszárd, Hungría, 7100
- Reclutamiento
- Research Site
-
Szolnok, Hungría, 5000
- Retirado
- Research Site
-
Székesfehérvár, Hungría, 8000
- Retirado
- Research Site
-
Törökbálint, Hungría, 2045
- Reclutamiento
- Research Site
-
-
-
-
-
Chennai, India, 600031
- Reclutamiento
- Research Site
-
Dwārka, India, 110075
- Reclutamiento
- Research Site
-
Jaipur, India, 302004
- Reclutamiento
- Research Site
-
Kolkata, India, 700099
- Reclutamiento
- Research Site
-
Marg Jaipur, India, 302004
- Retirado
- Research Site
-
Nagpur, India, 440001
- Reclutamiento
- Research Site
-
Nashik, India, 422011
- Reclutamiento
- Research Site
-
New Delhi, India, 11029
- Reclutamiento
- Research Site
-
New Delhi, India, 110085
- Reclutamiento
- Research Site
-
Surat, India, 395002
- Reclutamiento
- Research Site
-
Thiruvananthapuram, India, 695011
- Retirado
- Research Site
-
-
-
-
-
Bergamo, Italia, 24125
- Reclutamiento
- Research Site
-
Genoa, Italia, 16132
- Reclutamiento
- Research Site
-
Milan, Italia, 20141
- Reclutamiento
- Research Site
-
Milan, Italia, 20162
- Reclutamiento
- Research Site
-
Monza, Italia, 20052
- Reclutamiento
- Research Site
-
Padova, Italia, 35128
- Reclutamiento
- Research Site
-
Pavia, Italia, 27100
- Reclutamiento
- Research Site
-
Ravenna, Italia, 48100
- Reclutamiento
- Research Site
-
Roma, Italia, 00128
- Reclutamiento
- Research Site
-
Rozzano, Italia, 20089
- Reclutamiento
- Research Site
-
-
-
-
-
Bunkyō City, Japón, 113-8431
- Reclutamiento
- Research Site
-
Bunkyō City, Japón, 160-0023
- Reclutamiento
- Research Site
-
Fukuoka, Japón, 812-8582
- Reclutamiento
- Research Site
-
Fukuoka, Japón, 814-0180
- Reclutamiento
- Research Site
-
Hakodate-shi, Japón, 040-8611
- Reclutamiento
- Research Site
-
Hidaka-shi, Japón, 350-1298
- Reclutamiento
- Research Site
-
Hirakata-shi, Japón, 573-1191
- Reclutamiento
- Research Site
-
Hirosaki-shi, Japón, 036-8563
- Reclutamiento
- Research Site
-
Hiroshima, Japón, 730-8518
- Reclutamiento
- Research Site
-
Kanazawa, Japón, 920-8641
- Reclutamiento
- Research Site
-
Kashiwa, Japón, 227-8577
- Reclutamiento
- Research Site
-
Kawasaki-shi, Japón, 216-8511
- Reclutamiento
- Research Site
-
Kumamoto, Japón, 860-8556
- Reclutamiento
- Research Site
-
Matsusaka-shi, Japón, 515-8544
- Reclutamiento
- Research Site
-
Matsuyama, Japón, 790-0024
- Reclutamiento
- Research Site
-
Nagoya, Japón, 460-0001
- Reclutamiento
- Research Site
-
Niigata, Japón, 951-8566
- Reclutamiento
- Research Site
-
Okayama, Japón, 700-8558
- Reclutamiento
- Research Site
-
Osaka, Japón, 545-8586
- Retirado
- Research Site
-
Osakasayama-shi, Japón, 589-8511
- Reclutamiento
- Research Site
-
Sagamihara-shi, Japón, 252-0375
- Reclutamiento
- Research Site
-
Sapporo, Japón, 003-0804
- Reclutamiento
- Research Site
-
Takaoka-shi, Japón, 933-8555
- Reclutamiento
- Research Site
-
Takatsuki-shi, Japón, 569-8686
- Reclutamiento
- Research Site
-
Tokushima, Japón, 770-8503
- Reclutamiento
- Research Site
-
Tokyo, Japón, 104-0045
- Reclutamiento
- Research Site
-
Utsunomiya, Japón, 320-0834
- Reclutamiento
- Research Site
-
Yokohama, Japón, 221-0855
- Reclutamiento
- Research Site
-
-
-
-
-
Olsztyn, Polonia, 10-357
- Reclutamiento
- Research Site
-
Poznan, Polonia, 60-569
- Reclutamiento
- Research Site
-
Przemyśl, Polonia, 37-700
- Reclutamiento
- Research Site
-
Warsaw, Polonia, 02-781
- Reclutamiento
- Research Site
-
Warsaw, Polonia, 01-138
- Reclutamiento
- Research Site
-
-
-
-
-
Beijing, Porcelana, 100142
- Reclutamiento
- Research Site
-
Beijing, Porcelana, 101149
- Reclutamiento
- Research Site
-
Changchun, Porcelana, 130000
- Reclutamiento
- Research Site
-
Changsha, Porcelana, 410013
- Reclutamiento
- Research Site
-
Chengdu, Porcelana, 610000
- Reclutamiento
- Research Site
-
Chengdu, Porcelana, 610041
- Reclutamiento
- Research Site
-
Chongqing, Porcelana, 400030
- Reclutamiento
- Research Site
-
Fuzhou, Porcelana, 350014
- Reclutamiento
- Research Site
-
Guangzhou, Porcelana, 510080
- Reclutamiento
- Research Site
-
Hangzhou, Porcelana, 310006
- Reclutamiento
- Research Site
-
Hangzhou, Porcelana, 310022
- Reclutamiento
- Research Site
-
Hangzhou, Porcelana, 310016
- Reclutamiento
- Research Site
-
Harbin, Porcelana, 150049
- Reclutamiento
- Research Site
-
Hefei, Porcelana, 230601
- Reclutamiento
- Research Site
-
Hefei, Porcelana, 230031
- Retirado
- Research Site
-
Jinan, Porcelana, 250117
- Reclutamiento
- Research Site
-
Jining, Porcelana, 272011
- Retirado
- Research Site
-
Kunming, Porcelana, 650118
- Reclutamiento
- Research Site
-
Lanzhou, Porcelana, 730000
- Reclutamiento
- Research Site
-
Linhai, Porcelana, 317000
- Reclutamiento
- Research Site
-
Linyi, Porcelana, 276001
- Reclutamiento
- Research Site
-
Nanjing, Porcelana, 210009
- Reclutamiento
- Research Site
-
Nanning, Porcelana, 530021
- Reclutamiento
- Research Site
-
Nanning, Porcelana, 530000
- Reclutamiento
- Research Site
-
Shanghai, Porcelana, 200032
- Reclutamiento
- Research Site
-
Shanghai, Porcelana, 200030
- Reclutamiento
- Research Site
-
Shanghai, Porcelana, 200433
- Reclutamiento
- Research Site
-
Shenyang, Porcelana, 110022
- Reclutamiento
- Research Site
-
Taiyuan, Porcelana, 030000
- Reclutamiento
- Research Site
-
Tianjin, Porcelana, 300060
- Reclutamiento
- Research Site
-
Wenzhou, Porcelana, 325000
- Reclutamiento
- Research Site
-
Wuhan, Porcelana, 430022
- Reclutamiento
- Research Site
-
Wuhan, Porcelana, 430030
- Reclutamiento
- Research Site
-
Wuhan, Porcelana, 430010
- Reclutamiento
- Research Site
-
Wuhan, Porcelana, 430000
- Reclutamiento
- Research Site
-
Xi'an, Porcelana, 710061
- Reclutamiento
- Research Site
-
Yangzhou, Porcelana, 225001
- Reclutamiento
- Research Site
-
Zhengzhou, Porcelana, 450000
- Reclutamiento
- Research Site
-
Zhengzhou, Porcelana, 450008
- Reclutamiento
- Research Site
-
-
-
-
-
San Juan, Puerto Rico, 00909
- Reclutamiento
- Research Site
-
-
-
-
-
Cheltenham, Reino Unido, GL53 7AN
- Suspendido
- Research Site
-
Inverness, Reino Unido, IV2 3UJ
- Suspendido
- Research Site
-
London, Reino Unido, SW17 0QT
- Reclutamiento
- Research Site
-
London, Reino Unido, SW10 9NH
- Reclutamiento
- Research Site
-
London, Reino Unido, SE1 9RT
- Retirado
- Research Site
-
Norwich, Reino Unido, NR4 7UY
- Reclutamiento
- Research Site
-
Preston, Reino Unido, PR2 9HT
- Reclutamiento
- Research Site
-
Truro, Reino Unido, TR1 3LJ
- Reclutamiento
- Research Site
-
-
-
-
-
Bangkok, Tailandia, 10400
- Reclutamiento
- Research Site
-
Bangkok, Tailandia, 10700
- Reclutamiento
- Research Site
-
Hat Yai, Tailandia, 90110
- Reclutamiento
- Research Site
-
Muang, Tailandia, 22000
- Reclutamiento
- Research Site
-
Mueang, Tailandia, 20000
- Reclutamiento
- Research Site
-
Mueang, Tailandia, 32000
- Reclutamiento
- Research Site
-
-
-
-
-
Changhua, Taiwán, 500
- Aún no reclutando
- Research Site
-
Kaohsiung City, Taiwán, 80756
- Reclutamiento
- Research Site
-
New Taipei City, Taiwán, 220
- Reclutamiento
- Research Site
-
Taichung, Taiwán, 40447
- Reclutamiento
- Research Site
-
Taichung, Taiwán, 40705
- Reclutamiento
- Research Site
-
Tainan, Taiwán, 704
- Reclutamiento
- Research Site
-
Taipei, Taiwán, TAIWAN
- Reclutamiento
- Research Site
-
Taipei, Taiwán, 10002
- Reclutamiento
- Research Site
-
Taipei, Taiwán, 112
- Reclutamiento
- Research Site
-
Taipei, Taiwán, 0116
- Reclutamiento
- Research Site
-
Taoyuan, Taiwán, 333
- Reclutamiento
- Research Site
-
-
-
-
-
Adapazarı, Turquía (Türkiye), 54100
- Reclutamiento
- Research Site
-
Ankara, Turquía (Türkiye), 6200
- Reclutamiento
- Research Site
-
Ankara, Turquía (Türkiye), 06560
- Reclutamiento
- Research Site
-
Antalya, Turquía (Türkiye), 07070
- Reclutamiento
- Research Site
-
Diyarbakır, Turquía (Türkiye), 21280
- Reclutamiento
- Research Site
-
Istanbul, Turquía (Türkiye), 34030
- Reclutamiento
- Research Site
-
Istanbul, Turquía (Türkiye), 34890
- Reclutamiento
- Research Site
-
-
-
-
-
Da Nang, Vietnam, 550000
- Reclutamiento
- Research Site
-
Hanoi, Vietnam, 100000
- Reclutamiento
- Research Site
-
Ho Chi Minh City, Vietnam, 700000
- Reclutamiento
- Research Site
-
Ho Chi Minh City, Vietnam, 700000
- Retirado
- Research Site
-
Huế, Vietnam, 530000
- Retirado
- Research Site
-
Hà Nội, Vietnam, 100000
- Reclutamiento
- Research Site
-
Vinh, Vietnam, 460000
- Retirado
- Research Site
-
Vĩnh Yên, Vietnam, 280000
- Reclutamiento
- Research Site
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Histologically or cytologically documented non-squamous NSCLC.
- Stage IIIB or IIIC or Stage IV metastatic NSCLC (according to Edition 8 of the AJCC staging manual) not amenable to curative surgery or definitive chemoradiation.
- Absence of sensitising EGFR mutations, and ALK and ROS1 rearrangements, and absence of documented local test result for any other known genomic alteration for which there are locally approved and available targeted first-line therapies.
- Must provide tumor sample to determine PD-L1 status, TROP2 status and other biomarkers.
- Known tumour PD-L1 expression status defined as TC ≥ 50%
- At least one lesion, not previously irradiated that qualifies as a RECIST 1.1 target lesion at baseline
- ECOG performance status of 0 or 1
- Adequate bone marrow reserve and organ function
Exclusion Criteria:
- Prior systemic therapy for advanced/metastatic NSCLC.
- Squamous cell histology, or predominantly squamous cell histology NSCLC; mixed small cell lung cancer; NSCLC histology, sarcomatoid variant.
- History of another primary malignancy within 3 years
- Active or prior documented autoimmune or inflammatory disorders (with exceptions)
- Any evidence of severe or uncontrolled disease that makes it undesirable for the participant to participate in the study or that would jeopardies compliance with the protocol.
- Has clinically significant third-space fluid retention (for example pleural effusion) and is not amenable for repeated drainage.
- History of any ILD/pneumonitis, including radiation pneumonitis (apart from radiation pneumonitis that did not require steroids), or drug-induced ILD/pneumonitis, has current or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening.
- Has significant pulmonary function compromise, as determined by the investigator
- Spinal cord compression, or brain metastases unless participant treated and no longer symptomatic, radiologically stable, and who require no treatment with corticosteroids or anticonvulsants.
- History of leptomeningeal carcinomatosis
- Known clinically significant corneal disease
- Active infection with TB, HBV, HCV, Hepatitis A, or known HIV infection that is not well controlled
- History of active primary immunodeficiency
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Arm 1: Datopotamab Deruxtecan in Combination With Rilvegostomig
Participants in the Datopotamab Deruxtecan (Dato-DXd) in combination with Rilvegostomig group will receive Dato-DXd plus rilvegostomig as intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle. |
Datopotamab Deruxtecan IV (intravenous)
Otros nombres:
Rilvegostomig IV (intravenous)
Otros nombres:
|
|
Experimental: Arm 2: Rilvegostomig Monotherapy
Participants in the rilvegostomig monotherapy group will receive rilvegostomig as intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle. |
Rilvegostomig IV (intravenous)
Otros nombres:
|
|
Comparador activo: Arm 3: Pembrolizumab Monotherapy
Participants in the pembrolizumab group will receive pembrolizumab as intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle. |
Pembrolizumab IV (intravenous)
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Progression-Free Survival (PFS) in TROP2 biomarker positive participants.
Periodo de tiempo: Approximately 4 years
|
PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause. The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy, receives another anti-cancer therapy or clinically progresses prior to RECIST 1.1 progression, in the following population: • TROP2 biomarker positive population The measure of interest is the HR of PFS. PFS by investigator will be reported as a sensitivity analysis. |
Approximately 4 years
|
|
Overall Survival (OS) in TROP2 biomarker positive participants.
Periodo de tiempo: Approximately 6 years
|
OS is defined as the time from randomisation until the date of death due to any cause. The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy or receives another anti-cancer therapy, in the following population: • TROP2 biomarker positive population The measure of interest is the HR of OS. |
Approximately 6 years
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Progression-Free Survival (PFS) in the FAS population.
Periodo de tiempo: Approximately 4 years
|
PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause. The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy, receives another anti cancer therapy or clinically progresses prior to RECIST 1.1 progression, in the following population: • FAS population The measure of interest is the HR of PFS. PFS by investigator will be reported as a sensitivity analysis. |
Approximately 4 years
|
|
Overall Survival (OS) in the FAS population.
Periodo de tiempo: Approximately 6 years
|
OS is defined as the time from randomisation until the date of death due to any cause. The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy or receives another anti-cancer therapy, in the following population: • FAS population The measure of interest is the HR of OS. |
Approximately 6 years
|
|
Assessment of Objective Response Rate (ORR) by BICR in TROP2 biomarker positive and FAS populations
Periodo de tiempo: Approximately 4 years
|
ORR is defined as the proportion of participants who have a CR or PR, as determined by BICR per RECIST 1.1. The analyses will include all randomised participants, as randomised, with measurable disease at baseline, in the following populations:
The measure of interest is the difference of the ORR. ORR by investigator will be reported as a sensitivity analysis. |
Approximately 4 years
|
|
Assessment of Duration of Response (DoR) by BICR in TROP2 biomarker positive and FAS populations
Periodo de tiempo: Approximately 4 years
|
DoR is defined as the time from the date of first documented response until date of documented progression per RECIST 1.1, as assessed by BICR or death due to any cause. The analyses will include all randomised participants who have a response, as randomised, regardless of whether the participant withdraws from randomised therapy, receives another anti cancer therapy or clinically progresses prior to RECIST 1.1 progression, in the following populations:
|
Approximately 4 years
|
|
Participant-reported lung cancer symptoms of NSCLC and participant-reported GHS/QOL in participants treated with Dato-DXd in combination with rilvegostomig relative to pembrolizumab.
Periodo de tiempo: Approximately 6 years
|
Time to deterioration in: pulmonary symptoms (dyspnoea, cough, and chest pain) as measured by the NSCLC-SAQ, in overall lung cancer symptoms as measured by the NSCLC-SAQ, and in GHS/QoL as measured by the GHS/QoL scale from EORTC IL172. Time to deterioration is defined as the time from randomisation until the date of deterioration. Deterioration is defined as change from baseline that reaches a clinically meaningful deterioration threshold. The analyses will include all randomised participants, in the following populations:
|
Approximately 6 years
|
|
Participant-reported physical functioning in participants treated with Dato DXd in combination with rilvegostomig relative to pembrolizumab.
Periodo de tiempo: Approximately 6 years
|
Time to deterioration in physical functioning as measured by PROMIS Physical Function short form 8c. Time to deterioration is defined as the time from randomisation until the date of deterioration. Deterioration is defined as change from baseline that reaches a clinically meaningful deterioration threshold. The analyses will include all randomised participants, in the following populations:
|
Approximately 6 years
|
|
Pharmacokinetics (PK)
Periodo de tiempo: Approximately 6 years
|
Concentration of rilvegostomig, Dato-DXd, total anti TROP2 antibody, and MAAA 1181a (payload deruxtecan) in plasma or serum and PK parameters (peak and trough concentrations). |
Approximately 6 years
|
|
Immunogenicity
Periodo de tiempo: Approximately 6 years
|
Presence of ADA for Dato-DXd and rilvegostomig (confirmatory results, titres and neutralising antibodies for confirmed positive samples). |
Approximately 6 years
|
|
Second Progression-Free Survival (PFS2).
Periodo de tiempo: Approximately 6 years
|
PFS2 is defined as the time from randomisation to the earliest of the progression events (following the initial progression), subsequent to first subsequent therapy, or death. Progression event includes radiological (RECIST 1.1) or clinical disease progression. The date of second progression will be recorded by the investigator in the eCRF and defined according to local standard practice. The analyses will include all randomised participants, as randomised, regardless of whether the participant withdraws from subsequent therapy and regardless of missed visits, in the following populations:
|
Approximately 6 years
|
Otras medidas de resultado
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Safety of Dato-DXd in combination with rilvegostomig and rilvegostomig monotherapy as compared with pembrolizumab.
Periodo de tiempo: Approximately 6 years
|
Safety and tolerability will be evaluated in terms of AEs (graded by CTCAE Version 5.0). |
Approximately 6 years
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Investigadores
Investigadores
- Investigador principal: Suresh S. Ramalingam, MD, Emory University, Atlanta, Georgia, United States of America.
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- D7632C00001
- 2023-505077-32-00 (Identificador de registro: CTIS (EU))
- 2023 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.
All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Marco de tiempo para compartir IPD
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles.
For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Criterios de acceso compartido de IPD
When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool .
Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .